Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 76

1.

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia.

Langabeer SE, Haslam K, O'Brien D, Kelly J, Andrews C, Ryan C, Flavin R, Hayden PJ, Bacon CL.

Case Rep Hematol. 2016;2016:6545861. doi: 10.1155/2016/6545861. Epub 2016 Jan 21.

2.

Classical Hodgkin Lymphoma Arising Adjacent to a Breast Implant.

Ryan C, Ged Y, Quinn F, Walker J, Kennedy J, Gillham C, Pittaluga S, McDermott R, Vandenberghe E, Grant C, Flavin R.

Int J Surg Pathol. 2016 Feb 16. pii: 1066896916632587. [Epub ahead of print]

PMID:
26888955
3.

Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort.

Thorgeirsson T, Jordahl KM, Flavin R, Epstein MM, Fiorentino M, Andersson SO, Andren O, Rider JR, Mosquera JM, Ingoldsby H, Fall K, Tryggvadottir L, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2016 Mar;37(3):262-8. doi: 10.1093/carcin/bgw001. Epub 2016 Jan 16.

PMID:
26775038
4.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

PMID:
26615022
5.

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation.

Langabeer SE, Nolan J, Haslam K, Clarke L, Flavin R, Conneally E.

Case Rep Hematol. 2015;2015:703457. doi: 10.1155/2015/703457. Epub 2015 Aug 9.

6.

Case Study: Diffuse Large B-Cell Lymphoma Arising in Ovarian Mature Cystic Teratoma.

Maguire A, Castriciano G, Walker J, Molloy K, Quinn F, Osman N, Vandenberghe E, Jeffers M, Gaffney E, Flavin R.

Int J Gynecol Pathol. 2015 Sep;34(5):459-64. doi: 10.1097/PGP.0000000000000172.

PMID:
25996637
7.

Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.

Rafee S, Elamin YY, Joyce E, Toner M, Flavin R, McDermott R, Sheehy N, Hennessy B, O'Byrne K, Gleeson N, Osman N.

Tumori. 2015 Apr 28;101(2):e35-9. doi: 10.5301/tj.5000245.

PMID:
25744866
8.

A novel modification of the Stainsby procedure: surgical technique and clinical outcome.

Concannon E, MacNiocaill R, Flavin R, Kearns S.

Foot Ankle Surg. 2014 Dec;20(4):262-7. doi: 10.1016/j.fas.2014.06.006. Epub 2014 Jul 15.

PMID:
25457663
9.

Development of mapped stress-field boundary conditions based on a Hill-type muscle model.

Cardiff P, Karač A, FitzPatrick D, Flavin R, Ivanković A.

Int J Numer Method Biomed Eng. 2014 Sep;30(9):890-908. doi: 10.1002/cnm.2634. Epub 2014 Apr 7.

PMID:
24706576
10.

SPINK1 protein expression and prostate cancer progression.

Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA.

Clin Cancer Res. 2014 Sep 15;20(18):4904-11. doi: 10.1158/1078-0432.CCR-13-1341. Epub 2014 Mar 31.

11.

High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma.

Selvarajah S, Pyne S, Chen E, Sompallae R, Ligon AH, Nielsen GP, Dranoff G, Stack E, Loda M, Flavin R.

Clin Cancer Res. 2014 Mar 15;20(6):1521-30. doi: 10.1158/1078-0432.CCR-13-2090. Epub 2014 Feb 3.

12.

Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.

Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA.

J Natl Cancer Inst. 2013 Dec 18;105(24):1881-90. doi: 10.1093/jnci/djt332. Epub 2013 Nov 30.

13.

Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2354-63. doi: 10.1158/1055-9965.EPI-13-0668. Epub 2013 Oct 15.

14.

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.

Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin RI.

Oncogene. 2014 Aug 28;33(35):4424-32. doi: 10.1038/onc.2013.394. Epub 2013 Sep 30.

15.

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M.

Cancer Res. 2013 Nov 15;73(22):6770-9. doi: 10.1158/0008-5472.CAN-13-1145. Epub 2013 Sep 24.

16.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

17.

Gleason grade progression is uncommon.

Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M.

Cancer Res. 2013 Aug 15;73(16):5163-8. doi: 10.1158/0008-5472.CAN-13-0427.

18.

Comparison of gait after total ankle arthroplasty and ankle arthrodesis.

Flavin R, Coleman SC, Tenenbaum S, Brodsky JW.

Foot Ankle Int. 2013 Oct;34(10):1340-8. doi: 10.1177/1071100713490675. Epub 2013 May 13.

PMID:
23669163
19.

Development and progress of Ireland's biobank network: Ethical, legal, and social implications (ELSI), standardized documentation, sample and data release, and international perspective.

Mee B, Gaffney E, Glynn SA, Donatello S, Carroll P, Connolly E, Garrigle SM, Boyle T, Flannery D, Sullivan FJ, McCormick P, Griffin M, Muldoon C, Fay J, O'Grady T, Kay E, Eustace J, Burke L, Sheikh AA, Finn S, Flavin R, Giles FJ.

Biopreserv Biobank. 2013 Feb;11(1):3-11. doi: 10.1089/bio.2012.0028. Review.

20.

Pre-Treatment of platinum resistant ovarian cancer cells with an MMP-9/MMP-2 inhibitor prior to cisplatin enhances cytotoxicity as determined by high content screening.

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA.

Int J Mol Sci. 2013 Jan 22;14(1):2085-103. doi: 10.3390/ijms14012085.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk